Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Inclusion Criteria

• •1. Histologically confirmed adenocarcinoma of the breast
• •2. Female aged 20-75 years old at getting informed consent
• •3. HER2 negative disease (IHC 0/1+ or 2+ with FISH negative)
• •4. Documented estrogen receptor (ER) positive (\>=1% by IHC)
• •5. Inoperative locally advanced or metastatic breast cancer at enrolment
• •6. Performance status (ECOG): 0-1 at enrolment
• •7. Life expectancy of at least 3 months from enrolment
• •8. No prior systemic therapy for recurrent breast cancer (excluding hormone therapy)
• •9. No prior neo and/or adjuvant chemotherapy with taxane or adjuvant setting with a disease-free interval from completion of the taxane treatment to metastatic diagnosis of \>= 12 months
• •10. Patients with measurable lesion regarding with Response Evaluation Criteria in Solid Tumors(RECIST) criteria or who have evaluable lesion
• •11. Patients with only bone lesion will be acceptable if the osteolytic lesion has a measurable soft tissue component by MRI or CT
• •12. No influence on protocol treatment is considered in case prior therapy or examination.
• •13. Adequate following organ function within 2 weeks before starting treatment. The latest examination results should be adopted and blood transfusion or treatment of hematopoietic factor drugs is not allowed 2 weeks before examination.
• •* Absolute neutrophil count \>= 1500 /mm3 or white blood cell(WBC) count \>= 3000 /mm3
• •* Platelets \>=10 x 10000 /mm3
• •* Hb \>= 9 g/dL
• •* Total bilirubin \<= 1.5 mg/dL
• •* aspartate aminotransferase(AST) and alanine aminotransferase(ALT) \<= 100 international unit(IU)/L
• •* Serum creatinine \<= 1.5 mg/dL
• •* Urine dipstick for proteinuria \<= 1+
• •14. Written informed consent signed by patients before completing any treatment related procedure